Novel Anti-Seizure Compound ANAVEX 2-73 a Sigma-1 Receptor Agonist in Multiple Seizure ModelsDec 11, 2015The American Epilepsy Society Annual Meeting 2015, Philadelphia, PANell Rebowe, Christopher U. MisslingView Poster
The American Epilepsy Society Annual Meeting 2015, Philadelphia, PANell Rebowe, Christopher U. MisslingView Poster
Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX®2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio
Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer’s Disease
New Phase IIb/III Clinical Data Demonstrates Over Three Years of Continuous Treatment with Oral Blarcamesine to Significantly Benefit Early Alzheimer’s Disease Patients
